Health Ministers at PAHO approve rubella elimination, increased vaccination coverage

6 November 2006

Health ministers from the Americas at the Pan American Health Organization (PAHO) Directing Council have approved a new regional strategy to sustain immunization programs in the Americas, calling on countries to achieve vaccination coverage of more than 95% in all districts and to meet the target of eliminating rubella and congenital rubella syndrome by 2010.

In a resolution approved unanimously, health ministers also asked their countries to find new ways to finance and sustain immunization programs so they can introduce new vaccines against rotavirus, pneumococcus, and human papillomavirus, and to use the PAHO revolving fund to buy new and underutilized vaccines, including those against seasonal influenza and yellow fever.

Noting the successes of smallpox and polio eradication and measles elimination achieved through vaccination programs in the Americas, Gina Tambini, the PAHO's area manager for family and community health, stated: "this program with many achievements also has an unfinished agenda, and we have to work to extend the protection of vaccines to all vulnerable children and women in the region. We still have about one of every three children in Latin America and the Caribbean living in underserved districts, and they all require equitable access to the benefits of immunization."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight